



HAL
open science

Idiopathic inflammatory myopathies and the lung

Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien,
Isabelle Durieu, Vincent Cottin

► **To cite this version:**

Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien, Isabelle Durieu, et al.. Idiopathic inflammatory myopathies and the lung. *European Respiratory Review*, 2015, 24 (136), pp.216-238. 10.1183/16000617.00002015 . hal-01594100

HAL Id: hal-01594100

<https://hal.science/hal-01594100>

Submitted on 26 Sep 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - ShareAlike 4.0 International License



CrossMark

Idiopathic inflammatory myopathies and the lung

Jean-Christophe Lega^{1,2}, Quitterie Reynaud¹, Alexandre Belot³, Nicole Fabien⁴, Isabelle Durieu¹ and Vincent Cottin⁵

Affiliations: ¹Dept of Internal and Vascular Medicine, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, Lyon, France. ²UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, CNRS, Claude Bernard University Lyon 1, University of Lyon, Lyon, France. ³Dept of Pediatric Rheumatology, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, Lyon, France. ⁴Dept of Immunology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France. ⁵National Reference Centre for Rare Pulmonary Diseases, Dept of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, UMR 754, Claude Bernard University Lyon 1, University of Lyon, Lyon, France.

Correspondence: Jean-Christophe Lega, Dept of Internal and Vascular Medicine, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre-Bénite, France. E-mail: jean-christophe.lega@chu-lyon.fr

ABSTRACT Idiopathic inflammatory myositis (IIM) is a group of rare connective tissue diseases (CTDs) characterised by muscular and extramuscular signs, in which lung involvement is a challenging issue. Interstitial lung disease (ILD) is the hallmark of pulmonary involvement in IIM, and causes morbidity and mortality, resulting in an estimated excess mortality of 50% in some series. Except for inclusion body myositis, these extrapulmonary disorders are associated with the general and visceral involvement frequently found in other CTDs including fever, Raynaud's phenomenon, arthralgia, nonspecific cutaneous modifications and ILD, for which the prevalence is estimated to be up to 65%. Substantial heterogeneity exists within the spectrum of IIMs, and each condition is associated with various frequencies and subtypes of pulmonary involvement. This heterogeneity is partly related to the presence of various autoantibodies encompassing anti-synthetase, anti-MDA5 and anti-PM/Scl. ILD is present in all subsets of IIM including juvenile myositis, but is more frequent in dermatomyositis and overlap myositis. IIM can also be associated with other presentations of respiratory involvement, namely pulmonary arterial hypertension, pleural disease, infections, drug-induced toxicity, malignancy and respiratory muscle weakness. Here, we critically review the current knowledge about adult and juvenile myositis-associated lung disease with a detailed description of therapeutics for chronic and rapidly progressive ILD.



@ERSpublications

Interstitial lung disease is a leading cause of morbidity in dermatomyositis/polymyositis

<http://ow.ly/M1wB8>

Introduction

Idiopathic inflammatory myositis (IIM) [1, 2] is a group of rare connective tissue diseases (CTD) characterised by muscular and extramuscular signs, with lung involvement being a frequent and challenging issue [3–5]. IIM classically encompasses polymyositis, dermatomyositis and inclusion body myositis according to the first classification by Bohan and Peter [1, 2]. Because of the almost total absence of pulmonary involvement in inclusion body myositis, we will focus on dermatomyositis and polymyositis.

This version of this article has been amended. The amendment is outlined in the correction published in the September 2015 issue of the *European Respiratory Review* [DOI: 10.1183/16000617.50002015].

Received: March 11 2015 | Accepted after revision: April 22 2015

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

Provenance: Submitted article, peer reviewed.

Copyright ©ERS 2015. ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

The estimated annual incidence of dermatomyositis/polymyositis ranges from 6 to 10 per 1 000 000 [6]. Cutaneous signs, the hallmark of dermatomyositis, often are the initial presentation of disease and may or may not be associated with muscle manifestations. Erythematous rash over the extensor surface of the fingertips (Gottron's sign), eyelids (heliotrope rash), or upper chest or upper back and shoulders (V- or shawl sign) is considered specific of dermatomyositis. Clinically amyopathic dermatomyositis (CADM), or dermatomyositis sine myositis, is defined by the absence of clinically significant muscle symptoms and normal muscle enzymes for periods of >6 months, and is associated with an acute severe form of interstitial lung disease (ILD) [7]. Dissociation between the magnitude of pulmonary and muscular involvement is possible, and physicians may perform paraclinical tests for myositis including elevated muscular enzymes (creatinine kinase and aldolase), abnormal electromyograms, evocative muscle biopsy and an abnormal signal on muscle magnetic resonance imaging. Patients without overt muscular involvement are diagnosed as hypomyopathic dermatomyositis.

Substantial heterogeneity exists within the spectrum of IIMs, and each condition is associated with various frequencies of pulmonary involvement [8]. With the exception of inclusion body myositis, these extrapulmonary disorders are associated with the general and visceral involvement frequently found in other CTDs including fever, Raynaud's phenomenon, arthralgia, nonspecific cutaneous modifications, and lung involvement for which the prevalence is estimated to be up to 65% [8, 9]. The heterogeneity of the clinical spectrum of IIMs is partly related to the presence of various autoantibodies, known as myositis specific autoantibodies (MSA), that target a subset of aminoacyl-tRNA synthetases (ARSs) as well as components of the signal recognition particle (SRP) and nuclear helicase-ATPase Mi2 [10]. Anti-SRP autoantibodies are almost specific for a particular presentation of pauci-inflammatory necrotising myositis, whereas anti-Mi2 is found exclusively in dermatomyositis; both anti-SRP and anti-Mi2 autoantibodies are associated with a paucity of extramuscular features [8]. Anti-SRP autoantibodies are strongly associated with a subtype of acute immune-mediated necrotising myopathy characterised by proximal weakness secondary to pauci-inflammatory myocyte necrosis. Recently, other autoantibodies specific for dermatomyositis have been reported: anti-NXP2, anti-MDA5, anti-SAE and anti-TIF1 γ autoantibodies [11]. Additional autoantibodies, including anti-Ro60/SSa, anti-Ro52/TRIM21, anti-La/SSb, anti-U1RNP, PM/Scl and Ku, are frequent in other CTDs associated with myositis and especially in systemic sclerosis (SSc) [12] and are referred to as myositis-associated autoantibodies (MAA) [10].

ILD is the hallmark of pulmonary involvement in IIM, and causes morbidity and mortality, resulting in estimated excess mortality of 50% in some series [13, 14]. ILD may precede the occurrence of muscular signs in up to 20% of cases [15]. ILD is not uncommon in children and was experienced in 19% of juvenile forms of dermatomyositis (JDM) or polymyositis (JPM) [16]. It is present in all subsets of IIM, but is more frequent in dermatomyositis and overlap myositis. dermatomyositis, polymyositis and CADM can also be associated with other presentations of respiratory involvement, namely pulmonary arterial hypertension (PAH) [5], pleural disease [3], infections [17], drug-induced toxicity [18, 19], malignancy (cancer associated myositis (CAM)) [1, 2] and respiratory muscle weakness.

Here, we critically review the current knowledge about myositis-associated lung disease.

Classification of idiopathic inflammatory myositis

Several diagnostic criteria for IIM have been proposed. This section details four approaches to the classification of IIM.

Bohan and Peter's criteria

The criteria described by Bohan and Peter [1, 2], in 1975, probably remain the most widely used, despite the discovery of numerous autoantibodies and the refinement of histopathological techniques (table 1) [20]. Bohan and Peter's classification encompasses primary polymyositis, primary dermatomyositis, CAM, childhood dermatomyositis or polymyositis, and dermatomyositis or polymyositis associated with other CTDs (overlap myositis) [1]. This classification has severe limitations, which have been highlighted by several authors and include its development in a single centre, the absence of clear instructions to rule out other forms of myopathies (especially inclusion body myopathy), the lack of specific criteria for what should be considered a typical dermatomyositis rash, and the absence of external validation with estimation of sensitivity or specificity [21].

Classification based on autoantibodies

In 1991, LOVE *et al.* [22] proposed a new approach to classifying IIMs based on the description of clinical features associated with MSAs, classically encompassing anti-ARS, anti-SRP and anti-Mi2 autoantibodies (table 2). The anti-ARS autoantibodies identified a subset of patients with frequent ILD and relapsing myositis. The patients with anti-SRP autoantibodies presented with severe myositis, contrasting with those

TABLE 1 Classifications of idiopathic inflammatory myositis

Classification	Type of myositis	Subtype	Required assessments [#]	Description
Bohan and Peter's criteria	PM	Definite PM	2	Classical PM
		Probable PM	2	
		Possible PM	2	
	DM	Definite DM	2	Classical DM
		Probable DM	2	
Overlap myositis	CTM	2	Myositis with another CTD, irrespective of DM phenotype	
CAM	CAM	2	Myositis associated with cancer within 3 years	
ENMC criteria	PM	Definite PM	1	Classical PM
		Probable PM	3	
	DM	Definite DM	4	Classical DM
		Probable DM	3	
		Amyopathic DM	3	
	Immune mediated necrotising myopathy	Possible DM sine dermatitis	3	DM rash, positive skin biopsy Typical biopsy without cutaneous involvement
Nonspecific myositis		3	No DM rash, nonspecific abnormalities at biopsy	
Troyanov's criteria	PM	Pure PM	5	Myositis without extramuscular signs or antibodies
	DM	Pure DM	5	DM as the first manifestation, rashes persist until diagnosis, high cutaneous score, DM-specific antibodies
		Overlap myositis with DM features	5	Myositis as the first manifestation, low cutaneous score, no DM-specific antibodies
		Adermatomyopathic DM	5	DM rash or calcinosis, positive skin biopsy
	Overlap myositis	Clinically amyopathic DM	5	Amyopathic or hypomyopathic DM
		Overlap myositis	5	Myositis with at least one clinical overlap feature and/or an overlap autoantibody
	CAM	CAM	5	Clinical paraneoplastic features without an overlap autoantibody or anti-Mi-2

ENMC: European neuromuscular centre; PM: polymyositis; DM: dermatomyositis; CTM: myositis with other defined connective tissue disease; CTD: connective tissue disease; CAM: cancer associated myositis; MAC: membrane attack complex. [#]: the assessments are as follows. 1: physical examination, creatine phosphokinase and muscle biopsy; 2: assessments listed in 1 plus electromyography; 3: assessments listed in 2 plus muscular magnetic resonance imaging and autoantibodies; 4: physical examination and biopsy; 5: assessments listed in 2 plus autoantibodies.

with anti-Mi2 antibodies who had dermatomyositis with a good prognosis [22]. This approach was widely followed by many research groups and four pulmonary phenotypes related to distinct autoantibodies will be described in this review.

Anti-tRNA-synthetase autoantibodies-associated ILD

The spectrum of disease associated with anti-ARS autoantibodies was first described in 1990 [23]. Anti-ARS autoantibodies are the most frequent autoantibodies in patients with dermatomyositis (20%) and polymyositis (29%) (table 2) [8]. Anti-ARS autoantibodies are considered specific for IIMs and recognise a subset of ten ARSs [10, 24–28]. Out of all the anti-ARS autoantibodies identified (listed in table 2), anti-Jo1 (anti-histidyl) antibodies are the most commonly found. Anti-PL7 (anti-threonyl) and anti-PL12 (anti-analyl) antibodies are less frequent, whereas the others are exceedingly rare and are not commonly tested in autoimmunity laboratories. Several studies have shown an increased risk of ILD,

TABLE 2 Auto-antibodies in dermatomyositis and polymyositis with corresponding clinical spectrum

Autoantibodies	Antibody target	Frequency in polymyositis/ADM/JDM %	Frequency of ILD in adult/juvenile myositis %	Clinical spectrum	
				In adulthood	In childhood
Myositis-specific autoantibodies (MSA)					
Anti-tRNA synthetase		29/20/5			
Anti-Jo1 (PL1)	Histidyl-ARS	21/11/<3	66/63	Arthralgia, fever, RP, mechanic's hand, puffy finger	Arthralgia, fever, RP, mechanic's hand, sclerodactyly
Anti-PL7	Threonyl-ARS	5/2/<1	84/63		
Anti-PL12	Alanyl-ARS	2/3/<1			
Anti-KS	Asparaginyl-ARS	<1			
Anti-OJ	Isoleucyl-ARS	<1			
Anti-EJ	Glycyl-ARS	<1			
Anti-SC	Lysyl-ARS	<1			
Anti-JS	Glutaminy-ARS	<1			
Anti-YRS (Ha)	Tyrosyl-ARS	<1	<1		
Anti-Zo	Phenylalanyl-ARS	<1			
Dermatomyositis specific autoantibodies					
Anti-Mi2	Nucleosome remodelling deacetylase complex	1/9/4–10	4/0	Classical DM without extramuscular involvement	Mild or moderate JDM
Anti-NXP2 (MJ, p140)	Nuclear matrix protein 2	10/0–3/12–25	0/25	DM without extramuscular involvement, calcinosis	Mild or moderate JDM
Anti-MDA5 (CADM-140)	Melanoma differentiation-associated gene encoding RNA helicase	<1/14–46/7	Europe: 60; Asia: 90/Europe:19; Asia: 53	Amyopathic DM, severe cutaneous ulcers, rapidly progressive ILD	Severe cutaneous ulcers, RP-ILP, mediastinal emphysema
Anti-TIF1 γ (p155/140)	Transcriptional intermediary factor 1 γ	<1/10–30/14–29	<10/3	Cancer associated DM in 78% of cases	Mild or moderate JDM
Other MSA					
Anti-SRP	Signal recognition particle	5/1/<3	15/0	Necrotising myopathy	Severe JPM
Anti-HMGR (200–100)	3-hydroxy-3-methylglutaryl-coenzyme A reductase	10/<1/unknown	Unknown	Necrotising myopathy	Unknown
Anti-SAE	Small ubiquitin-like modifier activating enzyme	<1/5–10/1–9		DM	Unknown
Myositis-associated autoantibodies					
Anti-Ro/Ssa	RNP complexes with small cytoplasmic RNAs (hY-RNA)	12/13/0			
Anti-U1RNP	70 kDa, A and C polypeptides of U1 snRNP	5/6/6	7	DM, fever, RP, sclerodactyly	
Anti-PM/Scl (75 and 100 kDa)	PM/Scl complex encompassing C1D, PM-Scl-100 and PM-Scl-75 proteins of the human exosome	6/9/4	38	Fever, RP, sclerodactyly	
Anti-Ku	80 and 70 kDa DNA binding dimeric protein	2/1/0	27	Fever, RP, sclerodactyly	

ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; ILD: interstitial lung disease; SRP: signal recognition particle; ARS: aminoacyl-tRNA synthetase; RP: Raynaud's phenomenon; DM: dermatomyositis specific rash; RP-ILP: rapidly progressive ILD; JPM: juvenile polymyositis.

arthritis, Raynaud's phenomenon, mechanic's hand and fever in patients with myositis and anti-ARS autoantibodies as compared with seronegative controls, an association that is often referred to as the antisynthetase syndrome.

Anti-PM/Scl autoantibodies-associated ILD

Anti-PM/Scl autoantibodies were first identified in 1977 [29] and are directed against a nucleolar macromolecular complex of peptides of 75 kDa (PM/Scl 75 protein) and 100 kDa (PM/Scl 100 protein), with the former being considered the main autoantigen (table 2) [30]. Anti-PM/Scl autoantibodies have been found in 17% of patients with IIM-limited SSc overlap syndrome, compared with 7% of patients with isolated SSc [31], 9% of dermatomyositis patients and 6% of polymyositis patients [8]. Thus, anti-PM/Scl autoantibodies are usually classified as MAA (table 2). Pulmonary symptoms are concomitant of the other CTD manifestations in 11–58% of patients, and occur after the CTD features in 41–55% [19, 32]. The occurrence of ILD before the cutaneous and muscular manifestations of polymyositis or dermatomyositis is less frequently encountered than in subjects with anti-ARS autoantibodies [15, 19, 32].

Anti-MDA5 autoantibodies-related ILD

In 2005, SATO *et al.* [33] described an autoantibody targeting RNA helicase encoded by melanoma differentiation-associated gene 5 (anti-MDA5) that delineates a distinctive clinical pattern with rapidly progressive ILD and CADM with cutaneous ulcers. The anti-MDA5 autoantibodies are specific for dermatomyositis, and may be found in 7–13% of adult dermatomyositis patients (table 2) [34–36]. Clinically significant myositis is present in only 20% of patients with anti-MDA5 autoantibodies [37]. In a large European cohort of 285 childhood-onset IIM patients, anti-MDA5 autoantibodies were found in 7% of patients (table 2) and were associated with a higher frequency of mild muscular involvement and of radiological evidence of ILD (19%) [38].

Anti-NXP2 autoantibodies and ILD

Anti-NXP2 autoantibodies were first reported in JDM [39], and are less frequently found in adult patients with dermatomyositis, with a wide range of prevalence estimates (1.6–30%) averaging as 17% of dermatomyositis patients (table 2) [40–42]. In a cohort of adult patients with IIM [43], anti-NXP2 autoantibodies were the most prevalent antibodies, followed by anti-Jo1 autoantibodies, and were mutually exclusive of other MSAs. One recent case of ILD with subacute onset of dyspnoea and organising pneumonia has been reported in a patient with dermatomyositis associated with anti-NXP2 autoantibodies, suggesting that these markers should be included in the list of diagnostic tests in patients with ILD and suspected IIM [44].

Classification according to extramuscular features

Two recent studies by Troyanov and co-workers [11, 45] provided significant advances in the classification of IIMs. The first study introduced the concepts of “pure” polymyositis with poor muscular prognosis, and of overlap myositis defined by the occurrence of extramuscular signs with MSA/MAA autoantibodies (table 1) [45]. The frequency of polymyositis was only 9%, while the frequency of overlap myositis was 67% of the series. The second study described two phenotypes of dermatomyositis: pure dermatomyositis (dermatomyositis as the first manifestation, with high cutaneous score, chronic and recurrent cutaneous flares, no mechanic's hands or extramuscular involvement, presence of dermatomyositis-specific autoantibodies, perifascicular atrophy at biopsy and possible paraneoplastic aetiology) and overlap myositis with dermatomyositis features that are associated with poor survival (myositis as the first manifestation, isolated features of dermatomyositis rash, mechanic's hands, and anti-ARS, anti-PM/Scl autoantibodies or MSA) [11].

According to the definition of Troyanov and co-workers [11, 45], all patients presenting with IIM associated with ILD are classified as overlap myositis without distinction between clinical subtypes or prognosis. For this reason, this classification is of little value in the management of IIM-related ILD.

Classification based on muscle histopathology

Finally, the more complex and ambitious classification of the 119th European Neuromuscular Centre (ENMC) workshop (2003) includes inclusion body myositis, definite polymyositis, probable polymyositis, definite dermatomyositis, probable dermatomyositis, CADM, nonspecific myositis, and immune-mediated necrotising myopathy or necrotising autoimmune myopathy related to anti-SRP or 3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies (table 1) [46]. Unlike to the two other classifications based on clinical features and autoantibodies, the ENMC classification system is based on the use of muscle biopsy for classifying patients [46].

Overall, the classification of IIMs has evolved to better reflect the clinical and biological correlations of this spectrum of disease. The patients with IIMs and ILD seen by respiratory physicians mostly fall into the categories of dermatomyositis, classic polymyositis according Bohan and Peter's classification (or overlap myositis as defined by Troyanov and co-workers), and CADM.

Types of pulmonary involvement

A patient with pulmonary signs or complaints may suffer from a variety of chest manifestations in the setting of dermatomyositis/polymyositis. Physicians have to consider the following: direct pulmonary involvement (listed in order of decreasing frequency: ILD, group 1 or group 3 pulmonary hypertension, combined pulmonary fibrosis and emphysema (CPFE) syndrome, and pleural involvement); indirect pulmonary complications (infection, drug-induced lung disease, cancer, respiratory muscle weakness, congestive heart failure, *etc.*); and the possible combinations or associations with any of the mechanisms mentioned earlier.

Direct pulmonary involvement

Interstitial lung disease

Epidemiology

ILD is a frequent manifestation of dermatomyositis/polymyositis with the prevalence of clinically relevant ILD ranging from 17% to 36% [9, 47–51]. In a prospective series of patients with systematic assessment of lung involvement, the prevalence was estimated to be 65% [9]. ILD occurs after the diagnosis of polymyositis or dermatomyositis in up to 40% of patients, and precedes the diagnosis of overt CTD in 20–30% of cases [47, 52]. In large cohorts of JDM/JPM, ILD occurs in 8–13% of patients and thus seems to occur less frequently than in adult dermatomyositis [53, 54]. Risk factors for ILD in a patient with dermatomyositis/polymyositis include genetic predisposition [55, 56], some clinical signs such as arthralgia [47], and autoimmune features (table 2) [22, 56, 57]. After muscular involvement, dermatomyositis/polymyositis-associated ILD is the second major contributor to morbidity [47]. Up to half of patients with IIM-associated ILD may eventually die from respiratory failure [13]. The mortality rate is especially high in acute forms of ILD despite immediate and aggressive treatment [48, 58].

Clinical presentations

Usual presentation

The signs and symptoms related to ILD in IIM do not differ from idiopathic ILD, and include dyspnoea on exertion, cough, decreased exercise tolerance, digital clubbing and asthenia. Physicians who diagnose ILD have to pay particular attention to the extrapulmonary features of IIMs to distinguish secondary ILD from primary ILD. The assessment of such patients encompasses careful general (weight loss and fever), cutaneous (rash, sclerodactyly, Raynaud's phenomenon, calcinosis, cutaneous ulcers and mechanic's hands), muscular (loss of muscle mass, muscular testing and myalgia), and rheumatologic (arthralgia, arthritis and Jaccoud's deformity) examination. Subcutaneous calcinosis is present in ~25% of cases of JDM, in contrast to its rarity in adult onset dermatomyositis.

Beyond clinical assessment, the diagnosis of hypomyopathic forms of myositis requires creatine kinase and aldolase testing. In cases of high suspicion of IIM-related ILD (*e.g.* rash evocative of dermatomyositis or MSA positivity), supplementary investigations adapted for each patient comprise electromyography, muscular resonance magnetic imaging and muscle biopsy.

Testing for the presence of antinuclear autoantibodies completes the clinical evaluation; further testing for MSA or MAA depends on the pattern of nuclear fluorescence in most instances. The clinical spectrum associated with anti-ARS autoantibodies is highly heterogeneous and includes arthritis (62%), mechanic's hand (28%), fever (43%), Raynaud's phenomenon (47%) (fig. 1), myositis (57%) and ILD (70%) in its classical description [8, 15, 23]. Because of the high frequencies of nonspecific signs associated with anti-ARS autoantibodies (*i.e.* Raynaud's phenomenon, fever, hyperkeratosis and cracking of the skin on the fingers), we favour a revised definition of anti-ARS syndrome that was proposed by CONNORS *et al.* [51] based on major (arthritis, ILD and myositis) and minor criteria (table 3). In a meta-analysis of clinical manifestations, the frequency of ILD and fever was increased by 20–30% in patients with anti-ARS autoantibodies other than anti-Jo1 autoantibodies (especially anti-PL7 and anti-PL12 antibodies) as compared with those with anti-Jo1 autoantibodies [8]. By contrast, the frequency of mechanic's hands and of articular and muscular involvement was increased by 50% in patients with anti-Jo1 autoantibodies as compared with other anti-ARS antibodies [8]. Patients with anti-PL7 or anti-PL12 antibodies frequently present with isolated ILD, and are therefore mostly seen by respiratory specialists, whereas other signs are missing [15]. Patients with double positivity for anti-ARS and anti-U1RNP antibodies frequently experience manifestations of dermatomyositis (55%) and Raynaud's phenomenon (82%) [15]. In patients with anti-ARS antibodies, the presence of mechanic's hands may be associated with a higher risk of developing ILD [59].



FIGURE 1 Raynaud's phenomenon in a patient positive for anti-PL7 antibodies.

The clinical features described in patients with anti-PM/Scl antibodies largely overlap with those in patients with anti-ARS autoantibodies [19, 32]. Indeed, anti-PM/Scl positive patients commonly experience arthralgia (74%), Raynaud's phenomenon (63%), ILD (38%), fever (33%) and mechanic's hands (11%) [8]. Cutaneous manifestations of dermatomyositis and sclerodactyly are reported in 49% and 76% of cases, respectively [8]. The rash is usually mild and transient, with isolated heliotrope rash or Gottron's papules [11].

In cases with the presence of anti-MDA5 autoantibodies, digital ulcers are located mainly over the Gottron's papules and digital pulps or periungueal areas, but can occur in other sites of the dermatomyositis rash, *i.e.* the dorsal side of the elbows, knees, auricles or buttocks (fig. 2) [57, 58]. One European study reported an increased frequency of panniculitis [56]. Arthritis (80%), Raynaud's phenomenon (45%) and mechanic's hands (80%) (fig. 3) are frequently found [55]. Anti-MDA-5 autoantibodies have now been added to the differential diagnoses to consider, especially when the clinical features would suggest anti-ARS or anti-PM/Scl autoantibodies in dermatomyositis patients [55]. Importantly, screening for antinuclear autoantibodies may be negative in patients with anti-MDA5 autoantibodies, which therefore have to be measured specifically upon clinical suspicion [56].

Rapidly progressive ILD

Rapidly progressive ILD is defined by an acute interstitial pneumonia progressing over several weeks or a few months. Among all CTDs, this aggressive presentation of ILD is suggestive of IIM and especially of dermatomyositis, CADM or hypomyopathic dermatomyositis [60, 61]. Thus, physicians have to search thoroughly for minimal skin modifications or mild muscular involvement in the setting of rapidly progressive ILD.

The presence of anti-ARS autoantibodies seems relatively protective against rapidly progressive ILD, although this presentation has been reported [62, 63]. The detection of anti-MDA5 autoantibodies identifies dermatomyositis patients with a high risk of developing rapidly progressive ILD, with a pooled

TABLE 3 Proposed criteria for myositis associated with anti-tRNA synthetase antibody

Features the patient must have

Positive serological tests for an anti-tRNA synthetase antibody

Plus one major involvement:

- Evidence of overt or hypomyopathic myositis (elevated CPK levels, myalgia, proximal muscular weakness, positive muscular biopsy, electromyographic triad of myositis or MRI muscular oedema)
- Evidence of ILD according to ATS criteria
- Evidence of articular involvement (symmetrical inflammatory arthralgia or overt arthritis)

Or two minor involvements:

- Unexplained persistent fever
- Raynaud's phenomenon
- Mechanic's hands

CPK: creatine phosphokinase; MRI: magnetic resonance imaging; ILD: interstitial lung disease; ATS: American Thoracic Society. Reproduced and modified from [51], with permission from the publisher.



FIGURE 2 Clinical features associated with anti-MDA5 autoantibodies include severe cutaneous ulcers of a, b) the fingers and c) the dorsal side of the elbow.

sensitivity of 77% and a specificity of 86% in a meta-analysis of 631 dermatomyositis or polymyositis patients [64, 65]. Fulminant presentations with ILD, CADM and anti-MDA-5 autoantibodies may be especially frequent in Japanese patients compared with other east Asian or non-Asian patients [35, 64], although a publication bias cannot be excluded. In a Japanese retrospective series of 54 patients with JDM [66], 10 had rapidly progressive ILD and 19 had chronic ILD, illustrating the particularly frequent pulmonary involvement in the Asian population.

Pathogenesis

Aside from recent advances in patients with anti-MDA5 autoantibodies, the pathogenesis of dermatomyositis- or polymyositis-related ILD is poorly known, contrary to that of SSc [67]. Immunohistochemistry on muscle biopsy provides some clues as to immune mediated mechanisms. CD8⁺ T-cells are usually found in polymyositis with a diffuse cytotoxic effect leading to muscle cell necrosis [68], whereas B-cells and CD4⁺ T-cells predominate in perivascular areas in dermatomyositis and may be responsible for muscular vasculitis [67, 69]. In lung biopsy specimens of patients suffering from dermatomyositis- or polymyositis-associated ILD, numerous activated CD8⁺ lymphocytes are found in both



FIGURE 3 Mechanic's hands in a patient with anti-MAD5 positive dermatomyositis. Image courtesy of Sébastien Debarbieux (Dept of Dermatology, Centre Hospitalier Lyon Sud, Lyon, France).

affected and relatively preserved tissue. The proportion of these cells in the bronchoalveolar lavage (BAL) fluid might predict the outcome after treatment with corticosteroids, as CD8⁺ T-cells are significantly increased in corticosteroid-resistant cases of dermatomyositis- or polymyositis-associated ILD [70]. This observation needs confirmation, however, before it can be implemented in the clinic.

In addition, correlations are emerging between some genotypes and the clinical phenotype or prognosis. For example, a polymorphism in the promoter of the tumour necrosis factor- α gene is increased in dermatomyositis/polymyositis patients with ILD (OR 2.1, 95% CI 1.0–4.3) [71]. The HLA-DRB1*03 haplotype, a determinant factor in the development of ILD among patients with CTDs [72, 73], predicts a higher risk of ILD in dermatomyositis/polymyositis [74], irrespective of the myositis subtype or the presence of autoantibodies [56]. Anti-PM/Scl and anti-ARS antibodies also share the same prevalence of HLA-DRB1*03, DQA1*05 and DQB1*02 haplotypes [75, 76].

Recently, gain of function mutations in the *IFIH1* gene encoding the protein MDA5 were reported in association with various inflammatory conditions including a skin rash reminiscent of JDM skin lesions [77]. Anti-MDA5 is a cytosolic double strand RNA receptor, and gain of function mutations of *IFIH1* lead to enhanced type I interferon production. Similarly, gain of function mutations in the *TMEN173* gene encoding the DNA sensor STING (stimulator of interferon genes), which is responsible for enhanced type I interferon production, were found in patients with vascular involvement and severe ILD [78]. Taken together, these findings suggest that type I interferon may be a key cytokine linking anti-MDA5 autoantibodies to lung involvement and ILD.

Radiology

High-resolution computed tomography (HRCT) is essential for evaluation of ILD. Pulmonary HRCT scanning is a noninvasive and sensitive test, demonstrating evidence of pulmonary changes in all patients suffering from ILD. These changes are predominantly localised in the lower lobes, as reported by previous studies [47, 79]. Linear opacities, ground-glass attenuation (hyperattenuated areas in which the bronchi and vessels remain visible), reticulation and peribronchovascular thickening are the most common HRCT abnormalities at the initial imaging of ILD. Consolidation corresponding to areas with increased attenuation and decreased visibility of bronchial walls and vessels are commonly found, and correspond pathologically to areas of organising pneumonia. A combination of patchy areas of consolidation and reticulation is frequent, and suggestive of the diagnosis of myositis in subjects with ILD, especially of subacute or acute onset. Honeycombing (areas of small cystic spaces with thickened walls), traction bronchiectasis (bronchial dilation due to traction by fibrous tissue) and subpleural bands are less frequently observed [80].

Pathologic and imaging correlations in IIM are generally similar to those in the idiopathic setting. Overall, a variety of HRCT patterns may be observed in IIM-associated ILD, with especially those of organising pneumonia, nonspecific interstitial pneumonia (NSIP) (fig. 4) or mixed NSIP–organising pneumonia pattern, whereas the usual interstitial pneumonia (UIP) pattern (fig. 5) is less frequent [19]. However, studies that correlate imaging to pathology in the context of IIM are limited and suffer from selection bias, as clinicians tend to find lung biopsy indicated in the less typical cases. Therefore, caution must be exerted when interpreting the imaging, and HRCT patterns cannot be directly transposed into histological considerations.




FIGURE 4 High-resolution computed tomography from a patient with anti-Jo1 positive polymyositis showing basilar predominate reticulation and ground-glass opacity without honeycombing, in a pattern suggestive of nonspecific interstitial pneumonia.




FIGURE 5 High-resolution computed tomography from a patient with polymyositis showing honeycombing in a pattern consistent with usual interstitial pneumonia.

HRCT findings do not differ significantly between the various presentations of polymyositis- or dermatomyositis-ILD [81]; however, acute and subacute onset of ILD seem to be associated with more frequent and more extensive consolidation, which is the hallmark of this ILD subtype. Other HRCT features include diffuse patchy ground-glass opacity, basal irregular lines and some reticulation [63]. HRCT patterns at diagnosis can help predict the prognosis of patients with polymyositis- or dermatomyositis-ILD [82], and consolidation (mostly associated with a histological pattern of organising pneumonia) is generally reversible with treatment.

Polymyositis-ILD may be associated with a better prognosis than other forms. The HRCT patterns of dermatomyositis-ILD can be categorised in three groups to help clinical decisions [83]. Dominant ground-glass attenuation and/or reticular opacity without honeycombing, subpleural bands, and traction bronchiectasis are often associated with severe ILD and a possibly fatal outcome. Prominent consolidation is typical of acute onset ILD that responds well to corticosteroids and often immunosuppressive therapy [84]. The outcome of the HRCT pattern with ground-glass attenuation, predominant reticulation, bronchiectasis, and accessory findings is less predictable.

In patients with anti-ARS autoantibodies, the imaging patterns suggestive of NSIP and organising pneumonia predominate, and consolidation is present in half of the cases that resolve most often [85]. ILD related to anti-PL12 autoantibodies is more frequently associated with reticulation and traction bronchiectasis than anti-Jo1 autoantibodies. As expected, patients with anti-Jo1 autoantibodies who experience severe ILD more frequently have a UIP pattern on imaging than those with less progressive disease (54% *versus* 18%, OR 5.02, 95% CI 1.05–243) [59], suggesting that the imaging pattern of ILD may have prognostic significance in this setting, similar to what is observed in idiopathic interstitial pneumonia.

Pulmonary function tests

ILD is typically associated with restrictive lung function impairment (total lung capacity (TLC) and diffusing capacity of the lung for carbon monoxide (DLCO) <80% predicted). DLCO is commonly reduced in patients with ILD, often at an earlier stage of the disease than TLC and forced vital capacity (FVC). Pulmonary function tests add important information to HRCT to evaluate severity, as they only partially correlate with HRCT scores and pattern. In addition, pulmonary function is more sensitive to changes upon therapy than HRCT abnormalities.

Interpretation of pulmonary function tests may be difficult in IIMs, because of the potential coexistence of ILD, respiratory muscle weakness and/or PAH, with all three impairing DLCO. Moreover, a restrictive pattern may be driven by ILD but also by respiratory muscle weakness, the evaluation of which is often difficult to interpret. Conversely, pseudo-stabilisation of a restrictive pattern may be spuriously attributed to improved diaphragmatic strength [51]. In one study, pulmonary function parameters improved early in the course of disease in some patients treated with a combination of high-dose corticosteroids and immunosuppressive agents, and even normalised in some patients despite persisting radiographic changes [80]. The clinical significance of persisting abnormalities on HRCT despite normal lung function is currently unclear. Clinicians must be aware of the possible discrepancy between imaging and lung function in patients with dermatomyositis- or polymyositis-ILD to interpret response to therapy and outcome.

BAL cellular profile

When combined with the results of a careful history, physical examination and thoracic imaging, analysis of the BAL differential cell count can contribute to the diagnosis of ILD. BAL differential cell count *per se* does not predict the pathology pattern, however, nor does it predict the response to therapy. Thus, the main role of BAL is to rule out infection. BAL is crucially important in patients with acute or subacute onset ILD, which may correspond to bacterial infection or to ILD related to IIM. It is even more relevant in subjects with progressive disease despite corticosteroid treatment, in order to diagnose rare occult infections including atypical mycobacteria, *Pneumocystis jirovecii*, *Nocardia*, intracellular bacteria, cytomegalovirus and fungi, especially in immunocompromised patients.

Attempts have been made to correlate BAL cellular patterns to imaging or histological patterns, or to the clinical presentation. For example, increased lymphocytes and eosinophils in the BAL were higher in dermatomyositis-ILD than in polymyositis-ILD in one study [86]. The CD4⁺/CD8⁺ ratio was greater in CADM than in those with classic dermatomyositis and rapidly progressive ILD [62, 70, 87]. Increased neutrophil counts in BAL were associated with a worse outcome in dermatomyositis- or polymyositis-ILD in two studies [47, 63]. However, BAL cellular patterns lack reproducibility and have no clear clinical relevance or treatment implications. In addition, the BAL cellular profile is subnormal or cannot be categorised in a large proportion of cases despite the presence of ILD [88].

Pathology

ILD can present with a variety of histological patterns in the setting of IIM. Although the available studies suffer from selection bias, histopathological patterns include in order of decreasing frequency NSIP (65%), UIP (15%), organising pneumonia (9%) and diffuse alveolar damage (8%) according to pooled data from six independent series (table 4) [13, 47, 79, 86, 89, 90], whereas lymphocytic interstitial pneumonia was present in only 1% of patients. The pattern of organising pneumonia may be underrepresented in these series, as clinicians may identify consolidation as a feature associated with a relatively good response to treatment and prognosis, and refer less frequently for surgical biopsy. Two patterns may coexist in various amounts in a patient, with for example mixed patterns of organising pneumonia and NSIP. The patterns found are very similar to those observed in the idiopathic setting, with subtle differences noted including fewer fibroblastic foci, smaller honeycombing spaces, higher germinal centres and total inflammation scores in UIP-associated with CTD than in idiopathic UIP (idiopathic pulmonary fibrosis) [91]. A correlation was reported in one study between pathology and response to treatment, with a good prognosis in cases of organising pneumonia, contrary to those with patterns of diffuse alveolar damage or UIP as expected [86].

Overall, the pathology found in IIM-ILD is rather similar to that of idiopathic ILD. However, lung biopsy is now rarely performed in patients with CTD and ILD, as it generally does not alter management when compared with decisions based on less invasive procedures, *e.g.* clinical evaluation, pulmonary function tests, HRCT, and possibly BAL. A lung biopsy is discussed on an individual basis in rare cases with atypical imaging features, or when malignancy is considered.

Treatment

No randomised controlled trial has been performed to assess the efficacy and tolerance of corticosteroids and immunosuppressive drugs in patients with ILD associated with IIM. The efficacy of immunosuppressive drugs has mainly been reported in uncontrolled small retrospective series, which

TABLE 4 Results of lung histopathology in patients with dermatomyositis- or polymyositis- associated interstitial lung disease

First author [ref.]	Year	Number of biopsies/total cohort n/N	NSIP	UIP	OP	DAD	LIP	Unclassified
DOUGLAS [79]	2001	22/70	18	1	0	2	0	0
MARIE [47]	2002	11/36	4	5	2	0	0	0
COTTIN [13]	2003	17/17	11	2	2	0	1	1
TANSEY [89]	2004	13/13	7	1	5	0	0	0
FUJISAWA [86]	2005	13/28	8	3	0	3	0	0
WON HUH [90]	2007	9/99	4	4	0	1	0	0
Total n (%)		85	52 (61%)	16 (19%)	9 (11%)	6 (7%)	1 (1%)	1 (1%)

Where results were listed as minor pattern *versus* major pattern, only major patterns are reported. NSIP: nonspecific interstitial pneumonia; UIP: usual interstitial pneumonia; OP: organising pneumonia; DAD: diffuse alveolar damage; LIP: lymphocytic interstitial pneumonia. Reproduced and modified from [51], with permission from the publisher.

suggest a benefit of treatment but do not permit firm conclusions to be drawn. Thus, the indication for an immunosuppressive agent and the choice of the molecule are mostly based upon expert opinion, familiarity and experience of the clinician with a particular drug, and the tolerance profile. Treatments have to be initiated in cases of symptomatic or progressive ILD. Asymptomatic ILD must be carefully followed at diagnosis to determinate the disease evolution. Rapidly progressive ILD is poorly sensitive to corticosteroids alone and invariably requires combination with immunosuppressive therapies. Given a mortality rate close to 50%, the aim of therapy is to prevent progression to acute respiratory failure and death [51, 52].

Corticosteroids remain the cornerstone and first-line treatment of dermatomyositis- or polymyositis-associated ILD [13]. Oral regimens include 0.5–1 mg·kg⁻¹ of prednisone daily for 3–8 weeks, followed by a gradual taper. In severe cases, one to three daily pulses of 1000 mg intravenous methylprednisolone are administrated [13]. Response to first-line corticosteroid therapy is considered adequate in 90–100% of patients with chronic ILD (table 5) [59, 63, 100], with much lower response rates (7–44%) in rapidly progressive ILD, which usually requires additional immunosuppressive therapy (table 6) [58, 62, 63]. In addition to refractory disease, immunosuppressive therapies may be used in cases of relapsing disease, or as steroid-sparing agents. A number of drugs have been used, including azathioprine, methotrexate, cyclophosphamide, cyclosporin A, tacrolimus, rituximab and *i.v.* immunoglobulins [13, 19, 47, 48, 58, 94]; however, no large studies have been published on their use in this context.

The authors consider immunosuppressive therapy in addition to corticosteroids at diagnosis in patients with the most severe presentation, and in patients expected to poorly tolerate corticosteroids due to comorbidities, especially obesity. Other patients usually receive oral corticosteroids for the first 2–3 months; immunosuppressive agents may then be added to help reduce the dose of corticosteroids if tapering is difficult, and in those with an insufficient response to corticosteroids.

Azathioprine

Azathioprine, a derivative of 6-mercaptopurine agent, is an inhibitor of purine synthesis, thereby depleting cells of adenosine and guanosine nucleotides and inactivating T-cells, leading to immunosuppression [105]. It is usually administered orally at a dose of 2–3 mg·kg⁻¹ daily. Azathioprine is widely used in subjects with anti-ARS autoantibodies and other forms of dermatomyositis/polymyositis with ILD, either as a corticosteroid-sparing agent or as maintenance therapy, solely or sometimes following induction with cyclophosphamide [59, 79, 102]. Published data suggest improvement of ILD in ~75% of patients with

TABLE 5 Studies reporting treatment effects (improvement/stabilisation) of corticosteroids and immunosuppressive drugs for chronic forms of DM- or PM-associated ILD

First author [ref.]	Year	Total ILD subjects n	Series	Country	CS alone	AZA	MTX	CSA	FK506	CYC	RTX	MMF	CYC then AZA
FUJISAWA [86] [#]	2005	20	DM/PM	Japan	7/21	7/8		6/10		3/8			
SCHNABEL [92]	2003	10	DM/PM	Germany	6/6	2/2	2/2	1/1					
TAKADA [93]	2005	18	DM/PM	Japan				14/14 [§]	4/4 ^f				
WILKES [94]	2005	12	ARS-ILD	USA					12/12 [§]				
YAMASAKI [95]	2007	17	CADM/DM/PM	Japan					1/1 ^f		6/8		
IDEURA [96]	2007	9	CADM	Japan	2/8			5/5 [§]		1/1 [§]		9/9 [§]	
HAYASHI [83]	2008												
KOTANI [97]	2008	16	DM	Japan				3/4					
SEM [98]	2009	8	ARS-ILD	Norway							1/1		7/7 [§]
TILLIE-LEBLOND [63]	2008	17	ARS-ILD	France	5/5								
MARIE [99]	2012	5	ARS-ILD	France							5/5 ^f		
KOREEDA [100]	2010	13	ARS-ILD	Japan	6/6	1/1		4/5					
MORGANROTH [101]	2010	4	CADM/DM	USA								3/3	
MARIE [102] [¶]	2011	117	PM/DM	France	50/56	20/21				11/20		4/6 ^f	6/6
MARIE [59] [*]	2013	66	ARS-ILD	France	28/31	7/11				7/7		2/2 [§]	1/6
CAVAGNA [103]	2013	10	ARS-ILD	Italy				10/10 [§]					

Data are presented as improvement/stabilisation n/N, unless otherwise stated. DM: dermatomyositis; PM: polymyositis; ILD: interstitial lung disease; CS: corticosteroids; AZA: azathioprine; MTX: methotrexate; CSA: cyclosporin A; FK506: tacrolimus; CYC: cyclophosphamide; RTX: rituximab; MMF: mycophenolate mofetil; ARS-ILD: anti-tRNA synthetase positive ILD; CADM: clinically amyopathic dermatomyositis. [#]: probably encompassing rapidly progressive ILD (RP-ILD); [¶]: includes nine RP-ILD; ^{*}: includes 12 RP-ILD; [§]: second line; ^f: third line.

TABLE 6 Studies reporting treatment effects (survival) of corticosteroids and immunosuppressive drugs in rapidly progressive ILD associated with DM or PM

First author [ref.]	Year	Total ILD subjects n	Country	Series	CS alone	AZA	CSA	FK506	CYC	RTX	IVIG	CS + CSA + CYC	IGIV + CSA
SCHNABEL [92]	2003	10	Germany	DM-PM					10/10 [#] 2/2 [¶]				
KAMEDA [58]	2005	12	Japan	DM	1/12	0/3	4/5		0/1			5/10	
TAKADA [93]	2005	20	Japan	DM-PM			12/18	1/1 [¶]				1/1	
WILKES [94]	2005	3	USA	ARS-ILD				2/2 1/1 [#]					
IDEURA [96]	2007	9	Japan	ADM			5/9				1/1 [#]		
KOTANI [97]	2008	16	Japan	DM			3/4 5/5 [#]					2/3 2/3	
SUZUKI [104]	2009	5	Japan	ADM-PM									2/5 [#]
SEM [98]	2009	3	Norway	ARS-ILD						2/2 1/1			
TILLIE-LEBLOND [63]	2008	13	France	ARS-ILD	4/9								
MARIE [99]	2012	2	France	ARS-ILD						2/2 [¶]			
MUKAE [62]	2009	14	Japan	DM, CADM	1/14		3/13 [#]	1/1	2/4				
KOREEDA [100]	2010	1	Japan	ARS-ILD				1/1					
CAVAGNA [103]	2013	6	Italy	ARS-ILD				6/6					

Data are presented as n/N, unless otherwise stated. ILD: interstitial lung disease; DM: dermatomyositis; PM: polymyositis; CS: corticosteroids; AZA: azathioprine; CSA: cyclosporin A; FK506: tacrolimus; CYC: cyclophosphamide; RTX: rituximab; IGIV: intravenous immunoglobulins; ARS-ILD: anti-tRNA synthetase positive ILD; ADM: adult dermatomyositis; CADM: clinically amyopathic dermatomyositis. #: second line; ¶: third line.

chronic disease when it is used as first-line therapy (table 4) [59, 86, 92, 100, 102]. Whereas the results of azathioprine as second-line therapy were disappointing [102], in a very small series (seven patients) treatment with cyclophosphamide followed by azathioprine achieved remission in 58% of cases [59, 102], with better efficacy in cases with anti-ARS autoantibodies. Azathioprine has been used in very few patients with rapidly progressive ILD, but was unsuccessful (table 6) [58]. It should be kept in mind, however, that published retrospective data generally suffer from publication bias and may not be representative of the broader experience.

Methotrexate

Methotrexate is a folate antagonist, which inhibits dihydrofolate reductase. Because this enzyme is necessary in purine nucleotide synthesis, methotrexate administration results in decreased development and activation of T-lymphocytes. It is usually administered orally at a dose of 0.2–0.3 mg·kg⁻¹ weekly. Case reports and retrospective studies have suggested that methotrexate may be effective in the treatment of chronic ILD, although the treatment effect was not detailed (table 5) [13, 79, 92]. Overall, experience with methotrexate is very limited in patients with IIM-ILD, and respiratory physicians often are reluctant to use this drug because of possible drug-induced pneumonitis.

Cyclosporin A

Cyclosporin A is a calcineurin inhibitor, which inhibits transcription of interleukin-2 and other cytokines [105], mainly targeting T-cells. Cyclosporin A can be prescribed as a single drug, or in combination with other immunosuppressive drugs in severe cases [58, 93, 97]. It seems to be effective as both a first- or second-line therapy in rapidly progressive ILD [103, 106]. In chronic ILD, an efficacy of 55% has been reported when used as a first-line treatment (table 5) [86, 92, 97, 100]; all patients responded to treatment when cyclosporin A was used as second-line in three small series [93, 102, 103]. In rapidly progressive ILD, cyclosporin A may be used as a first-line or second-line agent with response ranges of 56–80%, and 23–80%, respectively (table 5) [62, 58, 93, 96, 97, 100]. However, the use of cyclosporin A is limited by the endothelial and renal toxicity (which is potentially lethal) [103]. Moreover, published experience with cyclosporin A largely emanates from groups in Asia, with much more limited experience in European and American centres, and therefore the risk–benefit ratio and position of this drug in the treatment algorithm are still unclear.

Tacrolimus

Tacrolimus is a second-generation calcineurin inhibitor with greater potency compared with cyclosporin A. Several retrospective studies suggest its utility as second- [94] or third-line of treatment in chronic ILD (table 5) [93, 95]. Its use as a first-line treatment or in refractory cases of rapidly progressing ILD needs to be further explored, with anecdotal responses reported in four patients in three studies [62, 93, 94].

Mycophenolate mofetil

Mycophenolate mofetil, a prodrug of mycophenolic acid, is an inhibitor of inosine monophosphate dehydrogenase, which is the rate-limiting enzyme in *de novo* synthesis of guanosine nucleotides, controlling T- and B-lymphocyte development [107]. The remission or stabilisation of ILD was obtained in 80% of patients with chronic ILD when used as a first or second-line of treatment (table 5) [59, 101, 105, 108]. Due to its relatively favourable safety profile, mycophenolate mofetil is increasingly used in patients with dermatomyositis- or polymyositis-ILD who require an immunosuppressive drug in combination with corticosteroids.

Cyclophosphamide

The alkylating agent cyclophosphamide, has been used to treat patients with dermatomyositis/polymyositis and rapidly progressive or chronic ILD, at a monthly dose of 0.6–0.7 mg·m⁻² *i.v.* Due to the risk of secondary malignancies, cyclophosphamide should be restricted to cases of refractory ILD [96] or rapidly progressive ILD [62, 92]. The reported efficacy rate ranges from 38% to 100% in chronic ILD [59, 86, 96, 102] and rapidly progressive ILD (tables 5 and 6) [92].

Rituximab

Rituximab is a chimeric monoclonal antibody targeting the CD20 protein, which is primarily found on the cell membrane of B-lymphocytes. Rituximab may be effective in rapidly progressive ILD and in chronic ILD with anti-ARS autoantibodies. It is administered with two doses of 700 mg·m⁻² or 1000 mg 2 weeks apart, or with four weekly infusions of 375 mg·m⁻². Corticosteroids are often prescribed concomitantly to obtain remission. Maintenance therapy is administered for 3–6 months after induction with rituximab, consisting of azathioprine [97] or possibly cyclophosphamide [98, 109]. In seven patients with anti-ARS autoantibodies, a second infusion of 1000 mg was administered 6 months after induction as maintenance (table 6) [99]. However, experience with rituximab is still very limited in IIM-ILD and it cannot be considered a first-line therapy.

Association of immunosuppressive drugs or therapeutics

Some authors reported the use of two combined immunosuppressive drugs, such as mycophenolate mofetil plus cyclophosphamide, mycophenolate mofetil plus methotrexate, or cyclophosphamide plus tacrolimus, with a rationale of additive effects and reportedly good safety [110]. Some of the regimens do not use corticosteroids [110], which are nevertheless considered mandatory in the majority of cases.

Intravenous immunoglobulins and plasma exchange have been used in patients with life-threatening pulmonary involvement. Despite a reported benefit of immunoglobulins on the muscle involvement, these treatments seem to have very limited effects on rapidly progressive ILD [96, 104], and therefore are seldom used to treat the lung disease.

Outcomes

The mean mortality rate related to ILD is 14% [47]. Some series reported mortality as high as 45% in patients with dermatomyositis, with deaths mainly caused by ILD [86]; however, this probably does not represent the majority of patients. ILD is a major cause of death in JDM. The mortality rate of patients with chronic ILD related to CADM is similar to that of patients with ILD related to typical dermatomyositis [13, 51].

A prognostic score is dramatically lacking in the management of IIM-related ILD. The mean prognosis factor is the clinical presentation of dermatomyositis- or polymyositis-associated ILD. The rapidly progressive presentation of ILD can lead to acute respiratory failure with diffuse alveolar damage (similar to acute idiopathic interstitial pneumonia, formerly named Hamman–Rich syndrome) [47], for which the mortality is 50–75% [48, 58]. The course of myositis is similar in patients with or without ILD [47], although the prevalence of myositis refractory to corticosteroid therapy alone was higher in polymyositis/dermatomyositis patients with ILD than in those without ILD in one series, possibly because of a higher rate of anti-tRNA synthetase autoantibodies in ILD patients [47].

The prognosis can vary according to the presence of MSA. The risk of acute evolution of ILD and mortality are generally not increased in patients with anti-ARS antibodies compared with the other

autoantibodies [52, 81, 96, 100]. Among patients with anti-ARS antibodies, the risk of pulmonary worsening and death seems to be similar in those with anti-Jo1 and non-Jo1 antibodies, but conclusions diverge according to the study [4, 8, 15, 111]. Prognosis of ILD associated with anti-PM/Scl autoantibodies is similar to other dermatomyositis- or polymyositis-associated ILD [19, 32]. Anti-PM/Scl patients have symptomatic pulmonary involvement with a globally favourable prognosis comparable to that of patients with anti-ARS autoantibodies [19]. Mortality from ILD is low in patients with anti-PM/Scl autoantibodies, ranging from 0% to 11% in two small retrospective cohorts [19, 32]. The survival rate of ILD associated with anti-MDA5 autoantibodies is lower than that of anti-ARS ILD [56].

Pulmonary arterial hypertension

Epidemiology

Precapillary pulmonary hypertension associated with dermatomyositis was first described in 1956 [112], and was reported more recently in case reports [113, 114] and short series [5]. The estimated frequency of pulmonary hypertension is 8% in patients with anti-ARS autoantibodies [5], and may be as high as 29% in patients with anti-PL7 autoantibodies [115]. Pulmonary hypertension can precede the diagnosis of myositis [116]; however, it is related to ILD (pulmonary hypertension group 3) in most, if not all, cases often after several years of disease duration [5]. These patients frequently experience clinical signs of SSc such as sclerodactyly, skin sclerosis, or digital ulcers [5]. In one series, arthralgia were less frequent at diagnosis in patients who developed pre-capillary pulmonary hypertension than in those who did not (38% versus 65%) [5].

Pathogenesis and pathology

Isolated pulmonary hypertension is very rare in dermatomyositis/polymyositis in the absence of ILD. Chronic hypoxic pulmonary vasoconstriction is one major factor driving the onset of pulmonary hypertension in patients with IIM-ILD; however, involvement of pulmonary vessels by the diffuse infiltrative and inflammatory process is likely to contribute to pathogenesis, as well as other less identified factors [5, 117]. In fact, pulmonary hypertension exists in the absence of significant hypoxia secondary to progressive ILD [5, 117]. Cutaneous features of SSc including Raynaud's phenomenon, digital ulcers, sclerodactyly and puffy fingers are frequently reported in patients with anti-ARS autoantibodies, and are more frequent in overt pulmonary hypertension [8, 118]. Two case reports in overt and hypomyopathic polymyositis describe severe right ventricular hypertrophy and plexogenic severe intimal fibrosis consistent with pulmonary arteriopathy at autopsy [113, 117]. Obliterative pulmonary vasculopathy (resulting from proliferation of endothelial and vascular smooth muscle cells) similar to that of SSc, but involving more proximal pulmonary arterioles, often coexists [117]. As in other forms of severe PAH, vascular remodelling involves all three layers of the pulmonary artery wall, with intimal thickening and medial hypertrophy, thus resembling changes seen in idiopathic PAH. The role in pathogenesis of the mechanisms described in SSc, ILD and pulmonary hypertension, namely vascular inflammation, perivascular fibrosis and thrombotic angiopathy, is unknown in IIM [119]. Similarly, the implication of growth factors (transforming growth factor, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-6) and the relative contributions of the endothelium-derived vasoactive factors (endothelin, nitric oxide and prostanoids) have not been explored in the pathogenesis of pulmonary hypertension associated with anti-ARS autoantibodies.

Treatment

Nonspecific treatments for pulmonary hypertension including phosphodiesterase-5 inhibitors (sildenafil and tadalafil), endothelin receptor antagonists (bosentan and ambrisentan) and prostacyclin derivatives (*i.v.* epoprostenol, subcutaneous treprostinil and nebulised iloprost) may be considered in patients with dermatomyositis- or polymyositis-associated with pulmonary hypertension [120–122]. Treatment should be reserved, however, to those rare patients with group 1 PAH with no significant ventilatory impairment resulting from ILD, whereas treatment is not recommended in those with group 3 pulmonary hypertension considered secondary to ILD [119]. It is unknown whether immunosuppressive therapies and corticosteroids (which may improve pulmonary hypertension in patients with systemic lupus) may be beneficial in patients with IIM and pulmonary hypertension [123, 124].

Outcome

Presence of both ILD and pulmonary hypertension is associated with dramatically low long-term survival, with a 3-year survival rate of 58% [5]. The prognosis of isolated pulmonary hypertension in dermatomyositis/polymyositis seems to be better, with a 3-year survival of 100% reported in seven patients [125]; however, experience is very limited.

Combined pulmonary fibrosis and emphysema

CPFE is a recently identified syndrome in smokers or ex-smokers characterised by dyspnoea that is often severe, preserved lung volumes, severely impaired gas exchange and an increased risk of pulmonary hypertension associated with a dismal prognosis [126, 127], and possibly lung cancer [128]. The diagnosis is based on the presence of both emphysema predominating in the upper lobes, and frequent paraseptal and ILD findings in the lower lung zones with typical velcro crackles at auscultation. Patients with CPFE experience a slower decline in FVC and DLCO than ILD patients without emphysema, and thus changes in these parameters alone may not be reliable indicators of disease progression [126, 127].

In a series of 34 patients with CTD, one patient was diagnosed as polymyositis, and another patient with myalgia, elevated creatine phosphokinase levels and Raynaud's phenomenon had anti-Jo1 autoantibodies. Patients with CTD-associated CPFE were younger and more frequently female compared with those with "idiopathic" (smoking-related) CPFE [129], with a similar prognosis. Patients with CTD-associated CPFE were more likely to be male and to be smokers than patients with CTD-associated ILD without emphysema [129], with no survival difference. Little is known about the prognosis and treatment of CPFE in the setting of dermatomyositis/polymyositis. Cessation of smoking is imperative.

Pleural involvement

Pneumomediastinum

Spontaneous pneumomediastinum has been reported as a rare complication of various types of ILD, especially ILD associated with dermatomyositis/polymyositis [3]. This event precedes the diagnosis of CTD in 18% of cases [3]. 70 cases, including two JDM [130, 131], were described, mainly secondary to dermatomyositis (95%) [3, 130–137]. ~6–8% of patients with polymyositis/dermatomyositis and ILD may develop a pneumomediastinum, leading to death in 35–66% of cases [3, 60, 138]. The presentation of pneumomediastinum ranges from acute respiratory failure to fortuitous diagnosis (33% of cases) [3, 139]. The predominant manifestations at onset are increased dyspnoea, cervical or facial swelling, subcutaneous emphysema, cervical pain and cough [3, 140]. Pneumothorax coexists in 40% of cases [3]. Pneumomediastinum is sometimes complicated by asymptomatic pneumorrhachis, *i.e.* epidural emphysema, diagnosed by HRCT [139]. Relapse of pneumomediastinum occurs in a quarter of cases [3].

Pathogenesis and pathology

In the setting of ILD, pneumomediastinum usually results from rupture of the subpleural or paracardial blebs due to the distortion of the lung architecture [3]. However, these abnormalities may have been underreported. The development of pneumothorax, pneumomediastinum, or both probably depends on the location of the rupture (peripheral for pneumothorax and adjacent to vessels for pneumomediastinum) [3]. An increase in intra-alveolar pressure during air travel [132] may have been a triggering factor in 45% of cases [3]. KONO *et al.* [138] hypothesised a relationship between the occurrence of pneumomediastinum and dermatomyositis-associated vasculitis leading to the necrosis of the bronchial wall. Patients with low vital capacity (VC) before pneumomediastinum are at higher risk of death [3].

Treatment

The treatment of pneumomediastinum consists of bed rest, thoracic drainage of the associated pneumothorax, and control of ILD by drug therapy, including corticosteroids in all cases, and occasionally methotrexate, *i.v.* immunoglobulins, cyclosporin A, azathioprine, mycophenolate mofetil, or rituximab [3, 130–137, 141].

Pneumothorax

Recurrent spontaneous pneumothorax was reported in a 17-year-old man diagnosed with JPM, in the absence of ILD [130]. Intra-operative observation and histopathological study demonstrated numerous bleb-like lesions below the visceral pleura. In other reported cases, pneumothorax was invariably secondary to ILD [97].

Pleural effusion

Exudative pleural effusion is a rare manifestation of dermatomyositis or polymyositis, and has mainly been described in case reports. In a series of dermatomyositis- or polymyositis-related ILD the prevalence was estimated as 5% [86]. It may be isolated or associated with ILD or pericardial effusion [142–144]. A CTD-specific myocarditis with congestive failure must be ruled out in cases of transudate effusion [144].

Indirect pulmonary complications

Infection

Infectious complications in dermatomyositis/polymyositis have been described in up to 37% of patients, with aspiration pneumonia being the most frequent infection. Patients receiving immunosuppressive drugs, or having oesophageal involvement, ventilatory insufficiency, cancer or myalgia are at higher risk of infections [145].

Pyogenic infection

Lungs are reported as the most common site of severe pyogenic infection in dermatomyositis/polymyositis patients (70% of cases) [17, 59, 86]. Aspiration pneumonia is a critical event in polymyositis/dermatomyositis patients with a prevalence of 7–20%, mainly within the first year after diagnosis [59, 60]. Most patients with aspiration pneumonia exhibited concomitant oesophageal involvement and ventilatory insufficiency related to respiratory striated muscle weakness [17].

Opportunistic infection

Pulmonary tuberculosis occurred in one (0.7%) patient receiving steroids in a series of 279 patients [17]. Pulmonary infection by *Mycobacterium xenopi* was reported in a patient treated with corticosteroids, and infection by *Mycobacterium peregrinum* in a patient taking corticosteroids and infliximab [17]. Other opportunistic lung infections secondary to corticosteroids and various immunosuppressive drugs described in dermatomyositis/polymyositis patients include pneumonia or pleural invasion by *Nocardia* spp. (seven cases) [146–148], pneumonia secondary to *Candida albicans* (one case) [145], *Aspergillus fumigatus* (three cases) [17, 149, 150], *Aspergillus niger* (one case) [150], lung abscess due to *Cryptococcus laurentii* (one case) [151], blastomycosis (one case) [152] and cytomegalovirus (four cases) [145, 153, 154]. *Pneumocystis jirovecii* infection was described after administration of prednisone, azathioprine, methotrexate, co-administration of methotrexate and azathioprine, and rituximab [17, 98].

Drug toxicity

Representative drugs that have been reported to cause drug-induced ILD in dermatomyositis/polymyositis are listed in table 6 [155]. An exhaustive list of medications with their reported pulmonary toxicities can be found online (www.pneumotox.com). Drug-induced ILD should be differentiated from diffuse lung diseases, including idiopathic ILD, ILD associated with CTD, acute and chronic hypersensitivity pneumonia, eosinophilic pneumonia, acute lung injury, acute respiratory distress syndrome, and *Pneumocystis* pneumonia. However, it is particularly difficult to determine whether new onset opacity at imaging is attributable to the underlying disease or to drug-induced ILD, as the signs and symptoms, HRCT pattern and biopsy findings are nonspecific. BAL may prove useful to identify microorganisms in culture, or to demonstrate increased eosinophil count or mixed lymphocytic and neutrophilic cellular patterns compatible with drug-induced ILD. The temporal relationship between the new/superimposed pulmonary manifestation and the initiation of the suspected medication may help to distinguish specific ILD related to IIM from drug-induced manifestations.

Malignancy

The association between IIM and cancer has been extensively studied in adults [1]. Among all malignancies, lung cancer is one of the leading causes of paraneoplastic forms of dermatomyositis/polymyositis, with a prevalence ranging from 1% to 5% in large series [156–159]. Conversely, paraneoplastic forms are extremely rare in JDM, contrasting with the relatively frequent malignancy observed in adults with dermatomyositis.

Dermatomyositis and polymyositis are significantly associated with a four-fold increase in the risk of malignancy compared with the general population [156]. The risk is maximal within the first year of follow-up and in Asian populations, and is higher in cases of severe dermatomyositis rash suggestive of intense vasculitis (cutaneous ulcers and periungual erythema), older age, male sex, higher C-reactive protein, elevated erythrocyte sedimentation rate and dysphagia [156, 160, 161]. Conversely, the frequency of cancer is lower among patients with anti-extractable nuclear antigen autoantibodies, anti-Jo1 autoantibodies and corresponding clinical features (ILD, Raynaud's phenomenon and arthralgia) [47, 160], but these findings cannot allow CAM to be ruled out [63].

In 2006, a new myositis-specific autoantibody (anti-p155) directed against transcriptional intermediary factor 1 γ (TIF1 γ) was described in dermatomyositis patients as a good marker of CAM, with an inverse (protective) association with ILD (table 2) [162]. KASUYA *et al.* [163] described the presence of TIF1 γ -bearing neoplasm in anti-p155/140 antibody-positive dermatomyositis and hypothesised the antigenic role of overexpressed TIF1 γ for the induction of paraneoplastic dermatomyositis. The clinical phenotype associated with these autoantibodies encompasses rashes evocative of typical dermatomyositis

as a first manifestation, including periungual changes, shawl and/or V-signs at diagnosis. The rashes persist despite the remission of myositis [11]. A meta-analysis of 312 adults from six studies reported that anti-TIF1 γ autoantibodies may be linked with cancer in dermatomyositis patients with a pooled sensitivity and specificity of anti-TIF1 γ for diagnosing CAM of 78% and 89%, respectively [164]. Anti-TIF1 γ had positive and negative predictive values of 58% and 95%, respectively.

Patients with CAM have a worse prognosis when compared with patients with idiopathic polymyositis or dermatomyositis. The mortality rate in this group of subjects is high and their life expectancy is related to the cancer and not to myositis itself. Since older age is a well-established risk factor for CAM, a thorough search for cancer should be performed in elderly patients with IIM.

Respiratory muscle weakness

Respiratory muscle involvement in IIM is extremely rare. The prevalence of respiratory failure due to respiratory muscle weakness is still unknown in this setting. The involvements of the respiratory muscles and the limb muscles are sometimes dissociated [165]. Patients suspected of having respiratory muscle involvement should be identified promptly because it is potentially life threatening [166].

In cases with moderate involvement, the standard pulmonary function tests may be unremarkable [167]. With progressive disease, restrictive physiology can be observed, with low TLC and VC, with normal FVC and DLCO [167]. Maximal inspiratory (and expiratory) pressures are decreased, as well as the sniff test (measurement of inspiratory pressure during a sniff). Supine respiratory function tests are useful for clinical diagnosis and respiratory risk stratification [167].

Patients with symptoms suggestive of respiratory muscle involvement should be closely monitored in hospital with a daily assessment of FVC using a bedside spirometer rather than peak flow [166]. Patients with FVC <15 mL.kg⁻¹ should be referred to an intensive care unit for monitoring and possible noninvasive mechanical ventilation [166]. The other critical predictive parameters include maximal inspiratory and expiratory pressures <30% predicted, and VC <55% predicted [167].

The treatment of respiratory weakness does not differ from that of other muscular involvement. In a retrospective series of 18 patients with myopathic restrictive respiratory involvement treated by corticosteroids or immunosuppressive drugs including azathioprine and cyclosporin A, complete remission was reported with therapy in 83% [48]. Two patients were treated with home mechanical ventilation [48]. The role of *i.v.* immunoglobulins in this condition is unclear.

Cardiac involvement

Oppenheim and colleagues first reported cardiac involvement in dermatomyositis in 1899 [168]. The prevalence of cardiac involvement in dermatomyositis/polymyositis varies between 9% and 72% according to the series and method of detection [169–173]. Clinically significant heart involvement is found in 10–15% of patients [174, 175]. Congestive heart failure, left ventricular diastolic dysfunction, coronary artery disease and arrhythmias may contribute to dyspnoea [167, 168, 176]. Pulmonary oedema due to myocarditis and/or cardiomyopathy usually occurs together with active muscular disease. Subclinical cardiac manifestations of myositis include various conduction blocks, and infra- or supraventricular arrhythmias in 30% of patients [167, 173]. The incidence of pericardial effusion is 15% [177].

Heart involvement is an independent factor of mortality in dermatomyositis/polymyositis [174]. Deaths related to myocarditis occurred in 1–2% of patients in a recent series of dermatomyositis/polymyositis [174]. Besides immunosuppressive therapy, cardiotropic drugs including β -blockers and angiotensin-converting enzyme inhibitors may also be of benefit to patients. Atrioventricular block has been successfully treated using pacemakers [173].

Summary

ILD is a leading cause of morbidity in dermatomyositis/polymyositis, especially rapidly progressive ILD. New autoantibodies associated with various clinical phenotypes have facilitated the diagnosis of IIMs, and contributed to better estimates of the risk and prognosis of ILD. Treatment depends on the severity and progression of ILD at diagnosis, and includes high-dose corticosteroids, often with additional immunosuppressive drugs (including azathioprine, mycophenolate mofetil or methotrexate in chronic ILD; and cyclosporin A or *i.v.* cyclophosphamide in rapidly progressive ILD). Further studies are needed to better understand the pathophysiology of ILD related to dermatomyositis/polymyositis, and to investigate the effectiveness and tolerance of targeted therapies in randomised controlled trials.

References

- 1 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975; 292: 344–347.
- 2 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). *N Engl J Med* 1975; 292: 403–407.

- 3 Le Goff B, Cherin P, Cantagrel A, *et al.* Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. *Arthritis Rheum* 2009; 61: 108–118.
- 4 Aggarwal R, Cassidy E, Fertig N, *et al.* Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. *Ann Rheum Dis* 2013; 73: 227–232.
- 5 Hervier B, Meyer A, Dieval C, *et al.* Pulmonary hypertension in antisynthetase syndrome: prevalence, a etiology and survival. *Eur Respir J* 2013; 42: 1271–1282.
- 6 Dobloug C, Garen T, Bitter H, *et al.* Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. *Ann Rheum Dis* 2014 [In press DOI: 10.1136/annrheumdis-2013-205127].
- 7 Gerami P, Schope JM, McDonald L, *et al.* A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. *J Am Acad Dermatol* 2006; 54: 597–613.
- 8 Lega JC, Fabien N, Reynaud Q, *et al.* The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. *Autoimmunity Rev* 2014; 13: 883–891.
- 9 Fathi M, Dastmalchi M, Rasmussen E, *et al.* Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. *Ann Rheum Dis* 2004; 63: 297–301.
- 10 Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. *Autoimmunity Rev* 2014; 13: 367–371.
- 11 Troyanov Y, Targoff IN, Payette MP, *et al.* Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. *Medicine (Baltimore)* 2014; 93: 318–332.
- 12 Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. *Curr Opin Rheumatol* 2007; 19: 580–591.
- 13 Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, *et al.* Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. *Eur Respir J* 2003; 22: 245–250.
- 14 Saketkoo LA, Ascherman DP, Cottin V, *et al.* Interstitial lung disease in idiopathic inflammatory myopathy. *Curr Rheumatol Rev* 2010; 6: 108–119.
- 15 Hervier B, Devilliers H, Stanciu R, *et al.* Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. *Autoimmunity Rev* 2012; 12: 210–217.
- 16 Sanner H, Aalokken TM, Gran JT, *et al.* Pulmonary outcome in juvenile dermatomyositis: a case-control study. *Ann Rheum Dis* 2011; 70: 86–91.
- 17 Marie I, Menard JF, Hachulla E, *et al.* Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. *Semin Arthritis Rheum* 2011; 41: 48–60.
- 18 Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. *Rheum Dis Clin North Am* 1994; 20: 513–528.
- 19 Lega JC, Cottin V, Fabien N, *et al.* Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? *J Rheumatol* 2010; 37: 1000–1009.
- 20 Oddis CV, Reed AM, Aggarwal R, *et al.* Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis Rheum* 2013; 65: 314–324.
- 21 Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. *J Rheumatol* 2013; 40: 550–564.
- 22 Love LA, Leff RL, Fraser DD, *et al.* A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. *Medicine* 1991; 70: 360–374.
- 23 Marguerie C, Bunn CC, Beynon HL, *et al.* Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. *Q J Med* 1990; 77: 1019–1038.
- 24 Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. *Ann N Y Acad Sci* 2010; 1184: 134–153.
- 25 Targoff I. Aminoacyl-tRNA (other than histidyl) synthetase autoantibodies. In: Peter J, Shoenfeld Y, eds. *Autoantibodies*. Amsterdam, Elsevier Science 1996; pp. 36–45.
- 26 Gelpi C, Kanterewicz E, Gratacos J, *et al.* Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. *Arthritis Rheum* 1996; 39: 692–697.
- 27 Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. *Joint Bone Spine* 2006; 73: 646–654.
- 28 Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. *J Clin Invest* 1993; 91: 2556–2564.
- 29 Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. *J Clin Invest* 1977; 59: 176–178.
- 30 Rajimakers R, Renz M, Wiemann C, *et al.* PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. *Arthritis Rheum* 2004; 50: 565–569.
- 31 D'Aoust J, Hudson M, Tatibouet S, *et al.* Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. *Arthritis Rheumatol* 2014; 66: 1608–1615.
- 32 Marie I, Lahaxe L, Benveniste O, *et al.* Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. *Br J Dermatol* 2010; 162: 337–344.
- 33 Sato S, Hirakata M, Kuwana M, *et al.* Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. *Arthritis Rheum* 2005; 52: 1571–1576.
- 34 Ghirardello A, Bassi N, Palma L, *et al.* Autoantibodies in polymyositis and dermatomyositis. *Curr Rheumatol Rep* 2013; 15: 335–342.
- 35 Hall JC, Casciola-Rosen L, Samedy LA, *et al.* Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. *Arthritis Care Res (Hoboken)* 2013; 65: 1307–1315.
- 36 Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, *et al.* Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. *J Immunol Res* 2014; 2014: 290797.
- 37 Cao H, Pan M, Kang Y, *et al.* Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. *Arthritis Care Res (Hoboken)* 2012; 64: 1602–1610.

- 38 Tansley SL, Betteridge ZE, Gunawardena H, *et al.* Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. *Arthritis Res Ther* 2014; 16: R138.
- 39 Gunawardena H, Wedderburn LR, Chinoy H, *et al.* Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. *Arthritis Rheum* 2009; 60: 1807–1814.
- 40 Sugiura K, Muro Y, Akiyama M. Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. *J Am Acad Dermatol* 2012; 67: e167–168.
- 41 Ichimura Y, Matsushita T, Hamaguchi Y, *et al.* Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. *Ann Rheum Dis* 2012; 71: 710–713.
- 42 Fiorentino DF, Chung LS, Christopher-Stine L, *et al.* Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. *Arthritis Rheum* 2013; 65: 2954–2962.
- 43 Ceribelli A, Fredi M, Taraborelli M, *et al.* Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. *Arthritis Res Ther* 2012; 14: R97.
- 44 Gossez M, Levesque M, Khouatra C, *et al.* Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody. *Eur Respir Rev* 2015; 24: 370–372.
- 45 Troyanov Y, Targoff IN, Tremblay JL, *et al.* Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. *Medicine (Baltimore)* 2005; 84: 231–249.
- 46 Hoogendijk JE, Amato AA, Lecky BR, *et al.* 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. *Neuromuscul Disord* 2004; 14: 337–345.
- 47 Marie I, Hachulla E, Cherin P, *et al.* Interstitial lung disease in polymyositis and dermatomyositis. *Arthritis Rheum* 2002; 47: 614–622.
- 48 Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, *et al.* Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. *Lupus* 2005; 14: 534–542.
- 49 Tani K, Tomioka R, Sato K, *et al.* Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. *J Med Invest* 2007; 54: 295–302.
- 50 Kang EH, Lee EB, Shin KC, *et al.* Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. *Rheumatology (Oxford)* 2005; 44: 1282–1286.
- 51 Connors GR, Christopher-Stine L, Oddis CV, *et al.* Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? *Chest* 2010; 138: 1464–1474.
- 52 Yoshifuji H, Fujii T, Kobayashi S, *et al.* Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. *Autoimmunity* 2006; 39: 233–241.
- 53 Shah M, Mamurova G, Targoff IN, *et al.* The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (Baltimore)* 2013; 92: 25–41.
- 54 Kobayashi S, Higuchi K, Tamaki H, *et al.* Characteristics of juvenile dermatomyositis in Japan. *Acta Paediatr Jpn* 1997; 39: 257–262.
- 55 Adimulam S, Chinoy H, Edge K, *et al.* In adult idiopathic inflammatory myopathies (IIM), the HLA-DRB1null03-associated increased risk for developing anti-Jo-1 antibodies is exacerbated in smokers. *Rheumatology* 2009; 48: i25.
- 56 Chinoy H, Salway F, Fertig N, *et al.* In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. *Arthritis Res Ther* 2006; 8: R13.
- 57 Hoshino K, Muro Y, Sugiura K, *et al.* Anti-MDA5 and anti-TIF1- γ antibodies have clinical significance for patients with dermatomyositis. *Rheumatology* 2010; 49: 1726–1733.
- 58 Kameda H, Nagasawa H, Ogawa H, *et al.* Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. *J Rheumatol* 2005; 32: 1719–1726.
- 59 Marie I, Josse S, Hatron PY, *et al.* Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. *Arthritis Care Res (Hoboken)* 2013; 65: 800–808.
- 60 Ye S, Chen XX, Lu XY, *et al.* Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. *Clin Rheumatol* 2007; 26: 1647–1654.
- 61 Hamaguchi Y, Kuwana M, Hoshino K, *et al.* Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. *Arch Dermatol* 2011; 147: 391–398.
- 62 Mukae H, Ishimoto H, Sakamoto N, *et al.* Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. *Chest* 2009; 136: 1341–1347.
- 63 Tillie-Leblond I, Wislez M, Valeyre D, *et al.* Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. *Thorax* 2008; 63: 53–59.
- 64 Chen Z, Cao M, Plana MN, *et al.* Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. *Arthritis Care Res (Hoboken)* 2013; 65: 1316–1324.
- 65 Gerfaud-Valentin M, Ahmad K, Piegay F, *et al.* Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies. *Rev Mal Respir* 2015; 31: 849–853.
- 66 Kobayashi N, Takezaki S, Kobayashi I, *et al.* Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. *Rheumatology* 2015 [In press DOI: 10.1093/rheumatology/keu385].
- 67 Wells AU, Denton CP. Interstitial lung disease in connective tissue disease—mechanisms and management. *Nat Rev Rheumatol* 2014; 10: 728–739.
- 68 Cherin P, Herson S, Crevon MC, *et al.* Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. *J Rheumatol* 1996; 23: 1135–1142.
- 69 Benveniste O, Cherin P, Maisonobe T, *et al.* Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. *J Immunol* 2001; 167: 3521–3529.

- 70 Kurasawa K, Nawata Y, Takabayashi K, *et al.* Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. *Clin Exp Immunol* 2002; 129: 541–548.
- 71 Furuya T, Hakoda M, Tsuchiya N, *et al.* Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. *J Rheumatol* 2004; 31: 1768–1774.
- 72 Gendi NS, Welsh KI, Van Venrooij WJ, *et al.* HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. *Arthritis Rheum* 1995; 38: 259–266.
- 73 Briggs DC, Vaughan RW, Welsh KI, *et al.* Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. *Lancet* 1991; 338: 661–662.
- 74 Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laqué R, *et al.* Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. *Arthritis Rheum* 2006; 55: 791–798.
- 75 Oddis CV, Okano Y, Rudert WA, *et al.* Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. *Arthritis Rheum* 1992; 35: 1211–1217.
- 76 Marguerie C, Bunn CC, Copier J, *et al.* The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. *Medicine (Baltimore)* 1992; 71: 327–336.
- 77 Rice GI, del Toro Duany Y, Jenkinson EM, *et al.* Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. *Nat Genet* 2014; 46: 503–509.
- 78 Liu Y, Jesus AA, Marrero B, *et al.* Activated STING in a vascular and pulmonary syndrome. *N Engl J Med* 2014; 371: 507–518.
- 79 Douglas WW, Tazelaar HD, Hartman TE, *et al.* Polymyositis-dermatomyositis-associated interstitial lung disease. *Am J Respir Crit Care Med* 2001; 164: 1182–1185.
- 80 Fathi M, Vikgren J, Boijesen M, *et al.* Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. *Arthritis Rheum* 2008; 59: 677–685.
- 81 Marie I, Josse S, Decaux O, *et al.* Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. *Autoimmunity Rev* 2012; 11: 739–745.
- 82 Tanizawa K, Handa T, Nakashima R, *et al.* The prognostic value of HRCT in myositis-associated interstitial lung disease. *Respir Med* 2013; 107: 745–752.
- 83 Hayashi S, Tanaka M, Kobayashi H, *et al.* High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. *J Rheumatol* 2008; 35: 260–269.
- 84 Mino M, Noma S, Taguchi Y, *et al.* Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. *Am J Roentgenol* 1997; 169: 83–87.
- 85 Debray MP, Borie R, Revel MP, *et al.* Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. *Eur J Radiol* 2015; 84: 516–523.
- 86 Fujisawa T, Suda T, Nakamura Y, *et al.* Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. *J Rheumatol* 2005; 32: 58–64.
- 87 Suda T, Fujisawa T, Enomoto N, *et al.* Interstitial lung diseases associated with amyopathic dermatomyositis. *Eur Respir J* 2006; 28: 1005–1012.
- 88 Meyer KC. The clinical utility of bronchoalveolar lavage in interstitial lung disease - is it really useful? *Expert Rev Respir Med* 8: 133–135.
- 89 Tansey D, Wells AU, Colby TV, *et al.* Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. *Histopathology* 2004; 44: 585–596.
- 90 Won Huh J, Soon Kim D, Keun Lee R, *et al.* Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. *Respir Med* 2007; 101: 1761–1769.
- 91 Song JW, Do KH, Kim MY, *et al.* Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. *Chest* 2009; 136: 23–30.
- 92 Schnabel A, Reuter M, Biederer J, *et al.* Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. *Semin Arthritis Rheum* 2003; 32: 273–284.
- 93 Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. *Autoimmunity* 2005; 38: 383–392.
- 94 Wilkes MR, Sereika SM, Fertig N, *et al.* Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. *Arthritis Rheum* 2005; 52: 2439–2446.
- 95 Yamasaki Y, Yamada H, Yamasaki M, *et al.* Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. *Rheumatology (Oxford)* 2007; 46: 124–130.
- 96 Ideura G, Hanaoka M, Koizumi T, *et al.* Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. *Respir Med* 2007; 101: 1406–1411.
- 97 Kotani T, Makino S, Takeuchi T, *et al.* Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. *J Rheumatol* 2008; 35: 254–259.
- 98 Sem M, Molberg O, Lund MB, *et al.* Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. *Rheumatology (Oxford)* 2009; 48: 968–971.
- 99 Marie I, Dominique S, Janvresse A, *et al.* Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. *Respir Med* 2012; 106: 581–587.
- 100 Koreeda Y, Higashimoto I, Yamamoto M, *et al.* Clinical and pathological findings of interstitial lung disease patients with anti-aminocyl-tRNA synthetase autoantibodies. *Intern Med* 2010; 49: 361–369.
- 101 Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. *Arthritis Care Res (Hoboken)* 2010; 62: 1496–1501.
- 102 Marie I, Hatron PY, Dominique S, *et al.* Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. *Arthritis Rheum* 2011; 63: 3439–3447.
- 103 Cavagna L, Caporali R, Abdi-Ali L, *et al.* Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. *J Rheumatol* 2013; 40: 484–492.
- 104 Suzuki Y, Hayakawa H, Miwa S, *et al.* Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. *Lung* 2009; 187: 201–206.
- 105 Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. *Autoimmunity Rev* 2011; 11: 6–13.

- 106 Labirua-Iturburu A, Selva-O'Callaghan A, Martinez-Gomez X, *et al.* Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. *Clin Exp Rheumatol* 2013; 31: 436–439.
- 107 Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacol* 2000; 47: 85–118.
- 108 Fischer A, Brown KK, Du Bois RM, *et al.* Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. *J Rheumatol* 2013; 40: 640–646.
- 109 Vandembroucke E, Grutters JC, Altenburg J, *et al.* Rituximab in life threatening antisynthetase syndrome. *Rheumatol Int* 2009; 29: 1499–1502.
- 110 Kalinova D, Rashkov R, Kolarov ZI. Tumor-associated myositides. *Rheumatology* 2009; 17: 18–25.
- 111 Hervier B, Devilliers H, Benveniste O. Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. *Ann Rheum Dis* 2013; 72: e18.
- 112 Caldwell IW, Aitchison JD. Pulmonary hypertension in dermatomyositis. *Br Heart J* 1956; 18: 273–276.
- 113 Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. *Chest* 1981; 79: 105–107.
- 114 Foris V, Kovacs G, Matucci-Cerinic M, *et al.* PL-7 positive antisynthetase syndrome and pulmonary hypertension. *J Rheumatol* 2013; 40: 1777–1779.
- 115 Kalluri M, Sahn SA, Oddis CV, *et al.* Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. *Chest* 2009; 135: 1550–1556.
- 116 Honma F, Shio K, Monoe K, *et al.* Primary biliary cirrhosis complicated by polymyositis and pulmonary hypertension. *Intern Med* 2008; 47: 667–669.
- 117 Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. *Arthritis Care Res (Hoboken)* 2010; 62: 425–429.
- 118 Koenig M, Fritzler MJ, Targoff IN, *et al.* Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. *Arthritis Res Ther* 2007; 9: R78.
- 119 Seeger W, Adir Y, Barbera JA, *et al.* Pulmonary hypertension in chronic lung diseases. *J Am Coll Cardiol* 2013; 62: Suppl., D109–D116.
- 120 Cavagna L, Prisco E, Montecucco C, *et al.* Pulmonary arterial hypertension in antisynthetase syndrome: comment on the article by Chatterjee and Farver. *Arthritis Care Res (Hoboken)* 2011; 63: 633–634.
- 121 Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. *Lupus* 2009; 18: 1006–1010.
- 122 Yaqub S, Moder KG, Lacy MQ. Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. *Mayo Clin Proc* 2004; 79: 687–689.
- 123 Mariette X, Brenot F, Brouet JC. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjogren's syndrome and polymyositis. *J Rheumatol* 1994; 21: 772–773.
- 124 Sanchez O, Sitbon O, Jais X, *et al.* Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. *Chest* 2006; 130: 182–189.
- 125 Condliffe R, Kiely DG, Peacock AJ, *et al.* Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. *Am J Respir Crit Care Med* 2009; 179: 151–157.
- 126 Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. *Curr Opin Pulm Med* 2012; 18: 418–427.
- 127 Cottin V, Nunes H, Brillet PY, *et al.* Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *Eur Respir J* 2005; 26: 586–593.
- 128 Girard N, Marchand-Adam S, Naccache JM, *et al.* Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients. *J Thorac Oncol* 2014; 9: 1162–1170.
- 129 Cottin V, Nunes H, Mouthon L, *et al.* Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. *Arthritis Rheum* 2011; 63: 295–304.
- 130 Chen L, Hu Y, Yao Y, *et al.* Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease. *Zhonghua Er Ke Za Zhi* 2012; 50: 465–469.
- 131 Dogra S, Suri D, Shah R, *et al.* Spontaneous pneumomediastinum: a rare complication of juvenile dermatomyositis. *Int J Rheum Dis* 2012; 15: e131–e133.
- 132 Ye Q, Zhang L, Tian X, *et al.* Exacerbation of pneumomediastinum after air travel in a patient with dermatomyositis. *Aviat Space Environ Med* 2011; 82: 734–736.
- 133 Cozzani E, Cinotti E, Felletti R, *et al.* Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. *Immunopharmacol Immunotoxicol* 2013; 35: 687–692.
- 134 Onishi S, Ono F, Hasegawa H, *et al.* Pneumomediastinum and massive subcutaneous emphysema associated with dermatomyositis. *Intern Med* 2012; 51: 3449–3450.
- 135 Rodrigues AJ, Jacomelli M, Scordamaglio PR, *et al.* Spontaneous pneumomediastinum associated with laryngeal lesions and tracheal ulcer in dermatomyositis. *Rev Bras Reumatol* 2012; 52: 796–799.
- 136 Kartik S, Bhakuni DS, Shanmuganandan K. Continuous diaphragm sign in amyopathic dermatomyositis. *Joint Bone Spine* 2013; 80: 102–103.
- 137 Saraya T, Tanaka Y, Ohkuma K, *et al.* Massive tension pneumomediastinum. *Intern Med* 2012; 51: 677.
- 138 Kono H, Inokuma S, Nakayama H, *et al.* Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. *Ann Rheum Dis* 2000; 59: 372–376.
- 139 Sandhya P, Keshava SN, Danda D, *et al.* Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. *Rheumatol Int* 2012; 32: 1415–1419.
- 140 Powell C, Kendall B, Wernick R, *et al.* A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease. *Chest* 2007; 132: 1710–1713.
- 141 Lee MA, Hutchinson DG. Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab. *Clin Rheumatol* 2010; 29: 945–946.
- 142 Mogulkoc N, Kabasakal Y, Ekren PK, *et al.* An unusual presentation of anti-Jo-1 syndrome, mimicking lung metastases, with massive pleural and pericardial effusions. *J Clin Rheumatol* 2006; 12: 90–92.
- 143 Derk CT, Sandorfi N, Curtis MT. A case of anti-Jo1 myositis with pleural effusions and pericardial tamponade developing after exposure to a fermented Kombucha beverage. *Clin Rheumatol* 2004; 23: 355–357.

- 144 Miyata M, Fukaya E, Takagi T, *et al.* Two patients with polymyositis or dermatomyositis complicated with massive pleural effusion. *Intern Med* 1998; 37: 1058–1063.
- 145 Marie I, Hachulla E, Cherin P, *et al.* Opportunistic infections in polymyositis and dermatomyositis. *Arthritis Rheum* 2005; 53: 155–165.
- 146 Ikeue T, Ueshima K, Watanabe S, *et al.* Pneumonia caused by *Nocardia nova*. *Nihon Kokyuki Gakkai Zasshi* 2001; 39: 492–497.
- 147 La Civita L, Battiloro R, Celano M. *Nocardia* pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy. *J Rheumatol* 2001; 28: 215–217.
- 148 Shah NM, Balakrishnan C, Mangat GK, *et al.* Pulmonary nocardial infection and pseudomonas infection of the tongue in a patient with dermatomyositis. *J Assoc Physicians India* 2001; 49: 850–851.
- 149 Lonneux M, Nolard N, Philippart I, *et al.* A case of lymphocytic pneumonitis, myositis, and arthritis associated with exposure to *Aspergillus niger*. *J Allergy Clin Immunol* 1995; 95: 1047–1049.
- 150 Kaiser L, Huguenin T, Lew PD, *et al.* Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. *Medicine (Baltimore)* 1998; 77: 188–194.
- 151 Lynch JP 3rd, Schaberg DR, Kissner DG, *et al.* *Cryptococcus laurentii* lung abscess. *Am Rev Respir Dis* 1981; 123: 135–138.
- 152 Rowin J, Amato AA, Deisher N, *et al.* Mycophenolate mofetil in dermatomyositis: is it safe? *Neurology* 2006; 66: 1245–1247.
- 153 Kasifoglu T, Korkmaz C, Ozkan R. Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis. *Clin Rheumatol* 2006; 25: 731–733.
- 154 Nishi K, Myoh S, Bandoh T, *et al.* An autopsy case of dermatomyositis associated with interstitial pneumonia probably due to cytomegalovirus infection. *Nihon Kyobu Shikkan Gakkai Zasshi* 1992; 30: 1975–1980.
- 155 Kubo K, Azuma A, Kanazawa M, *et al.* Consensus statement for the diagnosis and treatment of drug-induced lung injuries. *Respir Investig* 2013; 51: 260–277.
- 156 Yang Z, Lin F, Qin B, *et al.* Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. *J Rheumatol* 2015; 42: 282–291.
- 157 Chen YJ, Wu CY, Huang YL, *et al.* Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. *Arthritis Res Ther* 2010; 12: R70.
- 158 Kuo CF, See LC, Yu KH, *et al.* Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. *Br J Dermatol* 2011; 165: 1273–1279.
- 159 Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. *Brit J Cancer* 2001; 85: 41–45.
- 160 Wang J, Guo G, Chen G, *et al.* Meta-analysis of the association of dermatomyositis and polymyositis with cancer. *Br J Dermatol* 2013; 169: 838–847.
- 161 Lu X, Yang H, Shu X, *et al.* Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. *PLoS One* 2014; 9: e94128.
- 162 Targoff IN, Mamyrova G, Trieu EP, *et al.* A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis Rheum* 2006; 54: 3682–3689.
- 163 Kasuya A, Hamaguchi Y, Fujimoto M, *et al.* TIF1 γ -overexpressing, highly progressive endometrial carcinoma in a patient with dermatomyositis positive for malignancy-associated anti-p155/140 autoantibody. *Acta Derm Venereo* 2013; 93: 715–716.
- 164 Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, *et al.* Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. *Arthritis Rheum* 2012; 64: 523–532.
- 165 Maclean J, Singh RB, Sayeed ZA. Polymyositis presenting with respiratory failure. *Indian J Chest Dis Allied Sci* 2011; 53: 229–231.
- 166 Suresh E, Wimalaratna S. Proximal myopathy: diagnostic approach and initial management. *Postgrad Med J* 2013; 89: 470–477.
- 167 Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. *Clin Chest Med* 2010; 31: 501–512.
- 168 Péter A, Balogh Á, Szilágyi S, *et al.* Echocardiographic abnormalities in new-onset polymyositis/dermatomyositis. *J Rheumatol* 2015; 42: 272–281.
- 169 Danko K, Ponyi A, Constantin T, *et al.* Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. *Medicine (Baltimore)* 2004; 83: 35–42.
- 170 Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. *Semin Arthritis Rheum* 1986; 15: 168–178.
- 171 Denbow CE, Lie JT, Tancredi RG, *et al.* Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. *Arthritis Rheum* 1979; 22: 1088–1092.
- 172 Benbassat J, Gefel D, Larholt K, *et al.* Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. *Arthritis Rheum* 1985; 28: 249–255.
- 173 Zhang L, Wang GC, Ma L, *et al.* Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. *Clin Cardiol* 2012; 35: 686–691.
- 174 Danieli MG, Gambini S, Pettinari L, *et al.* Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. *Autoimmunity Rev* 2014; 13: 1048–1054.
- 175 Agrawal CS, Behari M, Shrivastava S, *et al.* The heart in polymyositis-dermatomyositis. *J Neurol* 1989; 236: 249–250.
- 176 Ungprasert P, Suksaranjit P, Spanuchart I, *et al.* Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. *Semin Arthritis Rheum* 2014; 44: 63–67.
- 177 Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, *et al.* Cardiac manifestations in dermatomyositis. *Clin Exp Rheum* 1996; 14: 373–379.